Subcutaneous and IV formulations of tocilizumab yielded similar rates of remission in patients with giant cell arteritis-associated aortitis, according to data published in Arthritis Care & Research.
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results